TAVR (n=195) SAVR (n=50)
p value
Clinical endpoints Clinical endpoints Clinical endpoints Clinical endpoints
In-hospital mortality 9 (4.6%) 6 (12.0%) 0.053
In-hospital mortality (TF-TAVR versus isolated surgical aortic valve intervention) 6/176 (3.4%) 3/40 (7.5%) 0.447
Stroke 3 (1.6%) 2 (4.0%) 0.272
Major vascular complication 15 (7.9%) 0 (0%) 0.046
Bleeding complications Bleeding complications Bleeding complications Bleeding complications
Life-threatening 12 (6.2%) 6 (12.0%) 0.161
Major 13 (6.7%) 14 (28.0%) <0.001
Life-threatening or major 25 (12.9%) 20 (40.0%) <0.001
Acute kidney injury Acute kidney injury Acute kidney injury Acute kidney injury
Stage 1
29 (15.0%)
15 (30.0%)
0.014
Stage 2 or 3
7 (3.6%)
9 (18.0%)
<0.001
Any stage
36 (18.7%)
24 (48.0%)
<0.001
New permanent pacemaker implantation 27 (13.9%) 6 (12.0%) 0.724
New onset atrial fibrillation 14 (7.3%) 15 (34.9%) <0.001
Length of ICU stay, days 1 [1-2] 3 [1-7] <0.001
Length of hospital stay, days 7 [5-10] 9 [6-16] 0.005
Echocardiographic endpoints Echocardiographic endpoints Echocardiographic endpoints Echocardiographic endpoints
Aortic regurgitation ≥2 20 (10.9%) 1 (2.6%) 0.137
Aortic regurgitation ≥3 10 (5.5%) 0 (0%) 0.217
Mean aortic gradient, mmHg 8.6 [6.1-12.0] 12.0 [8.0-14.0] 0.007